Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048258 | 0.84 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1LMNAMITFCYP1A2 | |
| SCHEMBL1559275 | 0.80 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1LMNAMITFCYP1A2 | |
| Hydrochloric Acid SCHEMBL3467161 | 0.78 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1LMNAMITFCYP1A2 | |
| SCHEMBL18380039 | 0.75 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1LMNAPTGS1PTGS2 | |
| SCHEMBL909516 | 0.74 | ALDH1A1 (0.66) | L3MBTL1ALDH1A1LMNA | |
| SCHEMBL18131178 | 0.74 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1LMNAPTGS1PTGS2 | |
| SCHEMBL4816241 | 0.74 | KDM4E (0.39) | ALDH1A1LMNATSHR | |
| SCHEMBL23113939 | 0.73 | PDK2 (0.34) | ALDH1A1TSHR | |
| SCHEMBL6683087 | 0.73 | KDM4E (0.36) | ALDH1A1LMNA | |
| SCHEMBL18049633 | 0.72 | AR (0.38) | ALDH1A1LMNACYP1A2CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3268004-B1 | PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-12-18 | — | — | EP | disclosed |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10040798-B2 | Pyrrolopyridazine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051029-A1 | PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| EP-3267996-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3268004-A1 | PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144847-A1 | PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144846-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051029-A1 | PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | L3MBTL1 1746/4885ALDH1A1 2006/4885LMNA 2284/4885 |
| US-10040798-B2 | Pyrrolopyridazine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | L3MBTL1 1746/4885ALDH1A1 2006/4885LMNA 2284/4885 |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | L3MBTL1 1305/4885ALDH1A1 2153/4885LMNA 1979/4885 |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | L3MBTL1 1305/4885ALDH1A1 2153/4885LMNA 1979/4885 |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | L3MBTL1 3324/4885ALDH1A1 3577/4885LMNA 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.